XT
CRDF icon

XTX Topco’s Cardiff Oncology CRDF Stock Holding History

XTX Topco’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Sell
97,400
-152,822
-61% -$243K ﹤0.01% 3448
2026
Q1 		$405K Buy
250,222
+30,865
+14% +$63.4K 0.01% 2229
2025
Q4 		$616K Buy
219,357
+63,196
+40% +$147K 0.02% 1415
2025
Q3 		$322K Buy
156,161
+25,809
+20% +$71.3K 0.02% 1456
2025
Q2 		$411K Buy
+130,352
New +$398K 0.02% 1235
2025
Q1 		– Sell
-40,763
Closed -$177K – 2516
2024
Q4 		$177K Sell
40,763
-79,621
-66% -$249K 0.01% 1604
2024
Q3 		$321K Buy
120,384
+36,947
+44% +$87.3K 0.02% 1140
2024
Q2 		$185K Buy
+83,437
New +$314K 0.02% 1269
2024
Q1 		– Sell
-33,453
Closed -$49.5K – 1911
2023
Q4 		$49.5K Buy
+33,453
New +$40.5K 0.01% 1234
2022
Q3 		– Sell
-55,081
Closed -$121K – 1142
2022
Q2 		$121K Buy
55,081
+29,927
+119% +$50.1K 0.05% 600
2022
Q1 		$62K Buy
+25,154
New +$89K 0.03% 571
2021
Q4 		– Sell
-13,824
Closed -$92K – 737
2021
Q3 		$92K Sell
13,824
-1,063
-7% -$6.68K 0.03% 573
2021
Q2 		$99K Buy
+14,887
New +$126K 0.03% 661

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco's CRDF Position: Q2 2026 in Review

XTX Topco reduced its Cardiff Oncology (CRDF) stake by 61% in Q2 2026, selling an estimated $243K and leaving 97,400 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #3448.

XTX Topco first reported a position in CRDF in Q2 2021 and has held it in 13 quarters since. The position peaked at $616K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • XTX Topco held 97,400 shares of Cardiff Oncology worth $127K as of Q2 2026.
  • XTX Topco sold 152,822 Cardiff Oncology shares in Q2 2026, an estimated $243K.
  • Cardiff Oncology made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3448 holding.
  • XTX Topco first reported a position in Cardiff Oncology in Q2 2021 and has held it in 13 quarters since.
  • XTX Topco's Cardiff Oncology position peaked at $616K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.